CING vs. VRPX, BPTS, EVOK, KTRA, MBIO, THAR, ZVSA, PCSA, GNPX, and NEXI
Should you be buying Cingulate stock or one of its competitors? The main competitors of Cingulate include Virpax Pharmaceuticals (VRPX), Biophytis (BPTS), Evoke Pharma (EVOK), Kintara Therapeutics (KTRA), Mustang Bio (MBIO), Tharimmune (THAR), ZyVersa Therapeutics (ZVSA), Processa Pharmaceuticals (PCSA), Genprex (GNPX), and NexImmune (NEXI). These companies are all part of the "pharmaceutical preparations" industry.
Virpax Pharmaceuticals (NASDAQ:VRPX) and Cingulate (NASDAQ:CING) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, community ranking, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.
In the previous week, Cingulate had 2 more articles in the media than Virpax Pharmaceuticals. MarketBeat recorded 3 mentions for Cingulate and 1 mentions for Virpax Pharmaceuticals. Cingulate's average media sentiment score of 1.44 beat Virpax Pharmaceuticals' score of 0.06 indicating that Virpax Pharmaceuticals is being referred to more favorably in the media.
Virpax Pharmaceuticals has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500. Comparatively, Cingulate has a beta of -0.95, meaning that its stock price is 195% less volatile than the S&P 500.
32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. Comparatively, 41.3% of Cingulate shares are owned by institutional investors. 6.2% of Virpax Pharmaceuticals shares are owned by company insiders. Comparatively, 38.4% of Cingulate shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Cingulate has a consensus price target of $8.00, suggesting a potential upside of 819.54%. Given Virpax Pharmaceuticals' higher possible upside, analysts clearly believe Cingulate is more favorable than Virpax Pharmaceuticals.
Virpax Pharmaceuticals is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks.
Virpax Pharmaceuticals' return on equity of 0.00% beat Cingulate's return on equity.
Cingulate received 4 more outperform votes than Virpax Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Virpax Pharmaceuticals an outperform vote while only 66.67% of users gave Cingulate an outperform vote.
Summary
Cingulate beats Virpax Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
Get Cingulate News Delivered to You Automatically
Sign up to receive the latest news and ratings for CING and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CING and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cingulate Competitors List
Related Companies and Tools
